News
SRNE
0.0030
-16.67%
-0.0006
Weekly Report: what happened at SRNE last week (1208-1212)?
Weekly Report · 2d ago
Weekly Report: what happened at SRNE last week (1201-1205)?
Weekly Report · 12/08 10:06
Weekly Report: what happened at SRNE last week (1124-1128)?
Weekly Report · 12/01 10:02
Weekly Report: what happened at SRNE last week (1117-1121)?
Weekly Report · 11/24 10:06
Weekly Report: what happened at SRNE last week (1110-1114)?
Weekly Report · 11/17 10:06
Weekly Report: what happened at SRNE last week (1103-1107)?
Weekly Report · 11/10 10:04
Weekly Report: what happened at SRNE last week (1027-1031)?
Weekly Report · 11/03 10:04
Weekly Report: what happened at SRNE last week (1020-1024)?
Weekly Report · 10/27 10:07
Weekly Report: what happened at SRNE last week (1013-1017)?
Weekly Report · 10/20 10:04
Weekly Report: what happened at SRNE last week (1006-1010)?
Weekly Report · 10/13 10:06
Weekly Report: what happened at SRNE last week (0929-1003)?
Weekly Report · 10/06 10:03
Weekly Report: what happened at SRNE last week (0922-0926)?
Weekly Report · 09/29 10:04
Weekly Report: what happened at SRNE last week (0915-0919)?
Weekly Report · 09/22 10:04
Weekly Report: what happened at SRNE last week (0908-0912)?
Weekly Report · 09/15 10:58
Weekly Report: what happened at SRNE last week (0901-0905)?
Weekly Report · 09/08 11:00
Weekly Report: what happened at SRNE last week (0825-0829)?
Weekly Report · 09/01 10:56
Weekly Report: what happened at SRNE last week (0818-0822)?
Weekly Report · 08/25 11:05
Weekly Report: what happened at SRNE last week (0811-0815)?
Weekly Report · 08/18 10:58
Weekly Report: what happened at SRNE last week (0804-0808)?
Weekly Report · 08/11 11:04
Weekly Report: what happened at SRNE last week (0728-0801)?
Weekly Report · 08/04 11:07
More
Webull provides a variety of real-time SRNE stock news. You can receive the latest news about Sorrento Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRNE
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.